GLUE — Monte Rosa Therapeutics Balance Sheet
0.000.00%
- $305.70m
- -$66.45m
- $75.62m
- 36
- 40
- 36
- 30
Annual balance sheet for Monte Rosa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 41.7 | 346 | 263 | 232 | 372 |
Net Total Receivables | — | — | 7.66 | 0.505 | 0.173 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 43.6 | 349 | 276 | 236 | 377 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4.62 | 12.3 | 61.9 | 62.6 | 56.3 |
Other Long Term Assets | |||||
Total Assets | 49.4 | 366 | 342 | 304 | 439 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 29.3 | 16.6 | 25.6 | 46.6 | 157 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 30.3 | 18.8 | 71 | 125 | 216 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 19 | 348 | 271 | 179 | 223 |
Total Liabilities & Shareholders' Equity | 49.4 | 366 | 342 | 304 | 439 |
Total Common Shares Outstanding |